JP2012516852A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012516852A5 JP2012516852A5 JP2011548414A JP2011548414A JP2012516852A5 JP 2012516852 A5 JP2012516852 A5 JP 2012516852A5 JP 2011548414 A JP2011548414 A JP 2011548414A JP 2011548414 A JP2011548414 A JP 2011548414A JP 2012516852 A5 JP2012516852 A5 JP 2012516852A5
- Authority
- JP
- Japan
- Prior art keywords
- dha
- unit dose
- pharmaceutical composition
- less
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 92
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 52
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 49
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 26
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 26
- 229930195729 fatty acid Natural products 0.000 claims description 26
- 239000000194 fatty acid Substances 0.000 claims description 26
- 150000004665 fatty acids Chemical class 0.000 claims description 26
- 239000002552 dosage form Substances 0.000 claims description 22
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 13
- 235000021342 arachidonic acid Nutrition 0.000 claims description 13
- 229940114079 arachidonic acid Drugs 0.000 claims description 13
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 13
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 13
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 13
- ITNKVODZACVXDS-YNUSHXQLSA-N ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate Chemical compound CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC ITNKVODZACVXDS-YNUSHXQLSA-N 0.000 claims description 9
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 4
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims description 3
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims description 3
- 230000007000 age related cognitive decline Effects 0.000 claims description 3
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 238000000034 method Methods 0.000 description 73
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 10
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 8
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 8
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 5
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 5
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 5
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 5
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 5
- 235000021360 Myristic acid Nutrition 0.000 description 5
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 5
- 239000005642 Oleic acid Substances 0.000 description 5
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 5
- 235000021314 Palmitic acid Nutrition 0.000 description 5
- 235000021355 Stearic acid Nutrition 0.000 description 5
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 5
- 235000020778 linoleic acid Nutrition 0.000 description 5
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 5
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 5
- 239000008117 stearic acid Substances 0.000 description 5
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 4
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 4
- -1 DHA ester Chemical class 0.000 description 4
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 4
- 239000005639 Lauric acid Substances 0.000 description 4
- 230000015654 memory Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000003920 cognitive function Effects 0.000 description 3
- SECPZKHBENQXJG-BQYQJAHWSA-N palmitelaidic acid Chemical compound CCCCCC\C=C\CCCCCCCC(O)=O SECPZKHBENQXJG-BQYQJAHWSA-N 0.000 description 3
- GWHCXVQVJPWHRF-KTKRTIGZSA-N (15Z)-tetracosenoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-KTKRTIGZSA-N 0.000 description 2
- XJXROGWVRIJYMO-SJDLZYGOSA-N Nervonic acid Natural products O=C(O)[C@@H](/C=C/CCCCCCCC)CCCCCCCCCCCC XJXROGWVRIJYMO-SJDLZYGOSA-N 0.000 description 2
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- GWHCXVQVJPWHRF-UHFFFAOYSA-N cis-tetracosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-UHFFFAOYSA-N 0.000 description 2
- VCDLWFYODNTQOT-UHFFFAOYSA-N docosahexaenoic acid methyl ester Natural products CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)OC VCDLWFYODNTQOT-UHFFFAOYSA-N 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- 241000199912 Crypthecodinium cohnii Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 241000598397 Schizochytrium sp. Species 0.000 description 1
- 241001298230 Thraustochytrium sp. Species 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- SOQKXJABGLKWQX-UHFFFAOYSA-N octacosa-4,7,10,13,16,19,22,25-octaenoic acid Chemical compound CCC=CCC=CCC=CCC=CCC=CCC=CCC=CCC=CCCC(O)=O SOQKXJABGLKWQX-UHFFFAOYSA-N 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 230000007596 spatial working memory Effects 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000003936 working memory Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14931009P | 2009-02-02 | 2009-02-02 | |
| US61/149,310 | 2009-02-02 | ||
| US18354809P | 2009-06-02 | 2009-06-02 | |
| US61/183,548 | 2009-06-02 | ||
| PCT/US2010/022952 WO2010088700A1 (en) | 2009-02-02 | 2010-02-02 | Methods for improving cognitive function and decreasing heart rate |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015057637A Division JP2015143248A (ja) | 2009-02-02 | 2015-03-20 | 認知機能改善および心拍数低下のための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012516852A JP2012516852A (ja) | 2012-07-26 |
| JP2012516852A5 true JP2012516852A5 (enExample) | 2013-03-21 |
Family
ID=42041547
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011548414A Withdrawn JP2012516852A (ja) | 2009-02-02 | 2010-02-02 | 認知機能改善および心拍数低下のための方法 |
| JP2015057637A Pending JP2015143248A (ja) | 2009-02-02 | 2015-03-20 | 認知機能改善および心拍数低下のための方法 |
| JP2018073345A Pending JP2018104477A (ja) | 2009-02-02 | 2018-04-05 | 認知機能改善および心拍数低下のための方法 |
| JP2019238726A Pending JP2020050675A (ja) | 2009-02-02 | 2019-12-27 | 認知機能改善および心拍数低下のための方法 |
| JP2022023007A Withdrawn JP2022059063A (ja) | 2009-02-02 | 2022-02-17 | 認知機能改善および心拍数低下のための方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015057637A Pending JP2015143248A (ja) | 2009-02-02 | 2015-03-20 | 認知機能改善および心拍数低下のための方法 |
| JP2018073345A Pending JP2018104477A (ja) | 2009-02-02 | 2018-04-05 | 認知機能改善および心拍数低下のための方法 |
| JP2019238726A Pending JP2020050675A (ja) | 2009-02-02 | 2019-12-27 | 認知機能改善および心拍数低下のための方法 |
| JP2022023007A Withdrawn JP2022059063A (ja) | 2009-02-02 | 2022-02-17 | 認知機能改善および心拍数低下のための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20100203123A1 (enExample) |
| EP (2) | EP2391361A1 (enExample) |
| JP (5) | JP2012516852A (enExample) |
| CN (3) | CN108324706A (enExample) |
| AU (2) | AU2016201382A1 (enExample) |
| CA (1) | CA2751275A1 (enExample) |
| HK (1) | HK1202243A1 (enExample) |
| WO (1) | WO2010088700A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8207363B2 (en) | 2009-03-19 | 2012-06-26 | Martek Biosciences Corporation | Thraustochytrids, fatty acid compositions, and methods of making and uses thereof |
| US20110177061A1 (en) * | 2009-07-10 | 2011-07-21 | Martek Biosciences Corporation | Methods of treating and preventing neurological disorders using docosahexaenoic acid |
| WO2012159092A2 (en) * | 2011-05-19 | 2012-11-22 | The Regents Of The University Of California | Medical food for cognitive decline |
| US20130084272A1 (en) * | 2011-09-29 | 2013-04-04 | Philippe Perrin | Compositions, kits and methods for nutritional supplementation with twelve carbon chain fatty acids and twelve carbon chain acylglycerols |
| US8168611B1 (en) | 2011-09-29 | 2012-05-01 | Chemo S.A. France | Compositions, kits and methods for nutrition supplementation |
| AU2014233421A1 (en) * | 2013-03-15 | 2015-09-24 | Genspera, Inc. | Methods of making cancer compositions |
| EP3626806B1 (en) | 2013-12-20 | 2024-06-19 | Mara Renewables Corporation | Methods of recovering oil from microorganisms |
| TR201503136A2 (tr) * | 2015-03-16 | 2016-09-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dronedaron ve esansiyel yağ asitlerinin farmasötik kompozisyonları. |
| US10851395B2 (en) | 2016-06-10 | 2020-12-01 | MARA Renewables Corporation | Method of making lipids with improved cold flow properties |
| WO2018116093A1 (en) | 2016-12-22 | 2018-06-28 | MARA Renewables Corporation | Methods for producing biomass rich in dha, palmitic acid and protein using a eukaryotic microorganism |
| JP7101087B2 (ja) * | 2018-09-05 | 2022-07-14 | 株式会社 伊藤園 | 軽度認知障害に対する緑茶成分の有効性評価方法 |
| FR3092968B1 (fr) * | 2019-02-22 | 2021-05-21 | Microphyt | Complement alimentaire |
| EP4009965A4 (en) * | 2019-08-08 | 2023-11-15 | Swinburne University of Technology | Uses of long-chain polyunsaturated fatty acids |
| AU2021245403A1 (en) | 2020-04-03 | 2022-11-24 | MARA Renewables Corporation | Microbial oils with high levels of omega-3 fatty acids |
| DE102020115238A1 (de) * | 2020-06-09 | 2021-12-09 | Pm-International Ag | Nahrungsergänzungsmittel und Nahrungsmittel |
| WO2022006496A1 (en) * | 2020-07-02 | 2022-01-06 | Pear Therapeutics, Inc. | Systems, methods, and devices for generating and administering digital therapeutic placebos and shams |
| CA3204546A1 (en) * | 2021-01-15 | 2022-07-21 | Cambridge Cognition Limited | Methods and systems of identifying individuals for perioperative neurocognitive disorder and/or post-viral cognitive impairment |
| WO2024155781A1 (en) * | 2023-01-18 | 2024-07-25 | Bioventures, Llc | Method of preventing and treating alzheimer's disease and related dementias with drugs inhibiting the interaction between 14-3-3g protein and hexokinase-1 protein |
| JP2025079778A (ja) * | 2023-11-10 | 2025-05-22 | ダイドーグループホールディングス株式会社 | 生理機能改善用の組成物 |
| WO2025100476A1 (ja) * | 2023-11-10 | 2025-05-15 | 国立大学法人京都大学 | 生理機能改善用の組成物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5407957A (en) | 1990-02-13 | 1995-04-18 | Martek Corporation | Production of docosahexaenoic acid by dinoflagellates |
| EP0707487B1 (en) * | 1993-06-09 | 2004-04-14 | Martek Biosciences Corporation | Methods and pharmaceutical compositions useful for treating neurological disorders |
| US20050027004A1 (en) * | 1993-06-09 | 2005-02-03 | Martek Biosciences Corporation | Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions |
| EP0776356B1 (de) | 1994-08-16 | 1999-06-30 | Dr. Frische GmbH | Verfahren zur gewinnung von nicht wasserlöslichen, nativen produkten aus nativen stoffgemengen mit hilfe der zentrifugalkraft |
| US6582941B1 (en) * | 1995-04-17 | 2003-06-24 | Japan As Represented By Director-General Of Agency Of Industrial Science And Technology | Microorganisms capable of producing highly unsaturated fatty acids and process for producing highly unsaturated fatty acids by using the microorganisms |
| JP3985035B2 (ja) * | 1995-09-14 | 2007-10-03 | 独立行政法人産業技術総合研究所 | （ｎ−６）系ドコサペンタエン酸含有油脂ならびに該油脂の製造方法および用途 |
| DE60012934T2 (de) | 1999-02-26 | 2005-08-25 | Martek Biosciences Corp. | Verfahren zum Abtrennen von einem Docosahexaensäure enthaltenden Triglycerid aus einem Triglyceridgemisch |
| WO2001051598A1 (en) | 2000-01-11 | 2001-07-19 | Monsanto Technology Llc | Process for making an enriched mixture of polyunsaturated fatty acid esters |
| PT1252324E (pt) | 2000-01-19 | 2010-12-16 | Martek Biosciences Corp | Processo de extracção sem solvente |
| DK1272049T3 (da) | 2000-04-12 | 2010-03-22 | Gea Westfalia Separator Gmbh | Fremgangsmåde til fraktionering af olie- og polær lipidholdige oprindelige råmaterialer under brug af alkohol og centrifugering |
| WO2002092540A1 (en) | 2001-05-14 | 2002-11-21 | Martek Biosciences Corporation | Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsatruated fatty acids from microbes, genetically modified plant seeds and marine organisms |
| US20070004678A1 (en) | 2001-05-14 | 2007-01-04 | Gerhard Kohn | Production and use of a polar lipid-rich fraction containing stearidonic acid and gamma linolenic acid from plant seeds and microbes |
| WO2003003981A2 (en) * | 2001-07-05 | 2003-01-16 | Vital Basics, Inc. | Compositions for improving mental performance |
| EP1503715A4 (en) | 2002-05-03 | 2005-07-06 | Martek Biosciences Corp | HIGH QUALITY LIPIDS AND METHODS FOR THE PRODUCTION THEREOF BY ENZYMATIC RELEASE FROM BIOMASS |
| JP5503846B2 (ja) * | 2005-01-24 | 2014-05-28 | プロノヴァ・バイオファーマ・ノルゲ・アーエス | アミロイドーシス関連疾患の治療のための医療品又は食料品の製造における、ｄｈａを含有する脂肪酸組成物の使用 |
| US8324276B2 (en) * | 2005-01-24 | 2012-12-04 | Pronova Biopharma Norge As | Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction |
| WO2006116755A2 (en) * | 2005-04-28 | 2006-11-02 | Trustees Of Tufts College | Synergitic effects of docosahexaenoic acid (dha) and carotenoid absorption of cognitive function |
| US10086009B2 (en) * | 2005-05-23 | 2018-10-02 | Massachusetts Institute Of Technologies | Compositions containing pufa and/or uridine and methods of use thereof |
| BRPI0613358A8 (pt) * | 2005-07-08 | 2017-12-26 | Dsm Ip Assets Bv | ácidos de gordura poli - insaturada para o tratamento da demência e condições relacionadas à pré-demência |
| WO2009002145A1 (en) * | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Lipid composition for improving function of brain functioning |
| WO2009006317A1 (en) | 2007-06-29 | 2009-01-08 | Martek Biosciences Corporation | Production and purification of esters of polyunsaturated fatty acids |
| US20110177061A1 (en) * | 2009-07-10 | 2011-07-21 | Martek Biosciences Corporation | Methods of treating and preventing neurological disorders using docosahexaenoic acid |
-
2010
- 2010-02-02 US US12/699,009 patent/US20100203123A1/en not_active Abandoned
- 2010-02-02 CN CN201810349154.XA patent/CN108324706A/zh active Pending
- 2010-02-02 CN CN2010800157224A patent/CN102365087A/zh active Pending
- 2010-02-02 EP EP10703592A patent/EP2391361A1/en not_active Withdrawn
- 2010-02-02 CN CN201410152946.XA patent/CN104042600A/zh active Pending
- 2010-02-02 JP JP2011548414A patent/JP2012516852A/ja not_active Withdrawn
- 2010-02-02 EP EP15162676.9A patent/EP2939671A1/en not_active Withdrawn
- 2010-02-02 CA CA2751275A patent/CA2751275A1/en not_active Abandoned
- 2010-02-02 WO PCT/US2010/022952 patent/WO2010088700A1/en not_active Ceased
-
2012
- 2012-12-13 US US13/713,980 patent/US20130172412A1/en not_active Abandoned
-
2015
- 2015-03-17 HK HK15102730.4A patent/HK1202243A1/xx unknown
- 2015-03-20 JP JP2015057637A patent/JP2015143248A/ja active Pending
-
2016
- 2016-03-03 AU AU2016201382A patent/AU2016201382A1/en not_active Abandoned
-
2017
- 2017-10-10 AU AU2017245327A patent/AU2017245327A1/en not_active Abandoned
-
2018
- 2018-04-05 JP JP2018073345A patent/JP2018104477A/ja active Pending
-
2019
- 2019-12-27 JP JP2019238726A patent/JP2020050675A/ja active Pending
-
2022
- 2022-02-17 JP JP2022023007A patent/JP2022059063A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012516852A5 (enExample) | ||
| AU2022200964B2 (en) | Compositions and methods for lowering triglycerides without raising ldl-c levels | |
| HRP20030035A2 (en) | Therapeutic combinations of fatty acids | |
| RU2018116572A (ru) | Композиции омега-3 полиненасыщенных жирных кислот в форме свободной кислоты, обогащенные DPA | |
| JPH11209279A (ja) | 体重減少および肥満処置の方法 | |
| TWI743022B (zh) | 包含10-羥基-2-癸烯酸之方法及組成物 | |
| JP2014512351A5 (enExample) | ||
| JP2017506233A5 (enExample) | ||
| JP6469261B2 (ja) | 多価不飽和遊離脂肪酸を含むミリカプセル製剤 | |
| Lin et al. | Altered essential fatty acid metabolism and composition in rat liver, plasma, heart and brain after microalgal DHA addition to the diet | |
| JP2020182497A5 (enExample) | ||
| WO2012108379A1 (ja) | 拡張性うっ血性心不全治療剤 | |
| JP5043677B2 (ja) | アルツハイマー型認知症予防・治療剤 | |
| JP5787615B2 (ja) | 左室拡張機能障害治療剤 | |
| JP2015145421A (ja) | 体重減少および肥満処置の方法 | |
| JP2014043465A (ja) | 体重減少および肥満処置の方法 | |
| JP2010159304A (ja) | 体重減少および肥満処置の方法 | |
| JP2004339240A (ja) | 体重減少および肥満処置の方法 | |
| JP2002234838A (ja) | 体重減少および肥満処置の方法 | |
| Calder | 8 Omega-3 (ω-3) Polyunsaturated Fatty Acids | |
| RU2017145265A (ru) | Фармацевтические композиции, содержащие epa и сердечно-сосудистое средство, и способы их применения |